Combination of Oxycodone and Morphine Produces Fewer Side Effects

QRxPharma’s formulation of MoxDuo IV produced positive results in its Phase 2 comparative proof-of-concept study, according to the company.

The study evaluated the efficacy and safety of the intravenous (IV) formulation of morphine plus oxycodone in comparison with IV morphine alone for the treatment of moderate to severe post-operative pain in patients after hip replacement surgery.

The findings demonstrated that the formulation resulted in fewer side effects and offered better pain relied than morphine alone.

“We are pleased to announce the encouraging data from this comparative study as it represents yet another important milestone demonstrating the significant efficacy and improved safety of our MoxDuo product portfolio across multiple Dual Opioid® formulations,” said Dr. John Holaday, managing director and chief executive officer, QRxPharma, in a press release.

The double blind study included 40 patients that were randomized into two treatment groups, one treated with morphine plus oxycodone IV or morphine IV. The patients had undergone total hip replacement surgery and developed moderate to severe pain. The dual formula was found to be well tolerated, with nausea and vomiting being the most common adverse events. None of these patients experienced low blood oxygen levels and indicated less risk of respiratory depression.